Tamarack Advisers LP lowered its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 59.8% during the third quarter, Holdings Channel reports. The firm owned 135,000 shares of the medical device companys stock after selling 201,000 shares during the period. AtriCure makes up about 0.7% of Tamarack Advisers LPs portfolio, making the stock its 24th largest position. Tamarack Advisers LPs holdings in AtriCure were worth $2,097,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the stock. BlackRock Group LTD boosted its stake in AtriCure by 5.5% in the third quarter. BlackRock Group LTD now owns 10,969 shares of the medical device companys stock worth $174,000 after buying an additional 576 shares during the period. BlackRock Advisors LLC raised its position in AtriCure by 11.5% in the second quarter. BlackRock Advisors LLC now owns 14,654 shares of the medical device companys stock worth $207,000 after buying an additional 1,517 shares in the last quarter. American International Group Inc. raised its position in AtriCure by 8.9% in the second quarter. American International Group Inc. now owns 18,093 shares of the medical device companys stock worth $256,000 after buying an additional 1,478 shares in the last quarter. Advisory Services Network LLC bought a new position in AtriCure during the third quarter worth approximately $260,000. Finally, Barclays PLC raised its position in AtriCure by 51.6% in the second quarter. Barclays PLC now owns 20,314 shares of the medical device companys stock worth $287,000 after buying an additional 6,918 shares in the last quarter. 79.35% of the stock is currently owned by institutional investors.
AtriCure, Inc. (NASDAQ:ATRC) opened at 16.47 on Monday. AtriCure, Inc. has a 52-week low of $13.44 and a 52-week high of $20.40. The firms 50-day moving average is $17.30 and its 200 day moving average is $16.83. The stocks market capitalization is $547.45 million.
A number of research analysts recently commented on the stock. Zacks Investment Research lowered shares of AtriCure from a buy rating to a hold rating in a research note on Wednesday, December 28th. Canaccord Genuity reiterated a buy rating and set a $20.00 price objective on shares of AtriCure in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $20.63.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the businesss stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $19.73, for a total value of $197,300.00. Following the transaction, the director now directly owns 24,162 shares in the company, valued at $476,716.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is owned by insiders.
(c) 2017 ITP Business Publishing Ltd. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers